U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06934226) titled 'A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis' on April 11.
Brief Summary: The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Study Start Date: April 25
Study Type: INTERVENTIONAL
Condition:
Plaque Psoriasis
Intervention:
DRUG: JNJ-77242113
JNJ-77242113 will be administered orally.
DRUG: Matching Placebo to JNJ-77242113
Matching placebo will be administered orally.
DRUG: Ustekinumab
Ustekinumab will be a...